Orange Book patents could face more challenges after appellate ruling
Court of Appeals for the First Circuit finds that Sanofi-Aventis improperly listed a patent for an “integral component” of a drug product and may be liable to antitrust claims
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Register now
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe now